Lacritin

Source: Wikipedia, the free encyclopedia.
LACRT
Identifiers
Gene ontology
Molecular function
Cellular component
Biological process
Sources:Amigo / QuickGO
Ensembl
UniProt
RefSeq (mRNA)

NM_033277

n/a

RefSeq (protein)

NP_150593

n/a

Location (UCSC)Chr 12: 54.63 – 54.63 Mbn/a
PubMed search[2]n/a
Wikidata
View/Edit Human

Lacritin is a 12.3 kDa

epithelial cells,[7] and corneal wound healing[8] Lacritin is thus a multifunctional prosecretory mitogen with cell survival activity. Natural or bacterial cleavage of lacritin releases a C-terminal fragment that is bactericidal.[9]

Most lacritin is produced by the

Dry eye is the most common disease of the LFU. A growing number of studies suggest that lacritin may be differentially downregulated in dry eye,[12] including contact lens-related dry eye.[13] Topical lacritin promotes tearing in rabbit preclinical studies.[14] In the Aire knockout mouse model of dry eye (considered similar to human Sjogren's syndrome), topical lacritin restores pilocarpine-induced tearing, largely eliminates lissamine green staining and reduces the size of inflammatory foci in the lacrimal gland.[15]

Lacritin cell targeting is dependent on the cell surface

G-protein-coupled receptor (GPCR) then appears to be ligated.[18] Targeted cells signal to NFAT and mTOR[18] if conditions are suitable for proliferation, or to AKT and FOXO3 under conditions of stress.[7]

Structure

Lacritin consists of 119

glycosylated.[20] Lacritin recombinantly generated in E. coli (no glycosylation) and lacritin in tears (glycosylated) differ in size with respective mobilities of ~18 and ~25 kDa by SDS-PAGE. With a predicted protein core molecular weight of 12.3 kDa, it is possible that mobility is partially retarded by lacritin's amphipathic alpha helices. Predicted pI of lacritin's core protein is 5.[12]

Lacritin is subject to crosslinking by

syndecan-1.[17] Accordingly, crosslinked lacritin binds syndecan-1 poorly[21]
and is inactive.

Several lacritin splice variants have been detected in Aceview,[22] from NEIBank EST data.[23] Lacritin-b (11.1 kDa; pI 5.3) lacks the sequence SIVEKSILTE. Lacritin-c (10.7 kDa; pI 4.6) displays a novel C-terminus that should be incapable of binding syndecan-1, and lacks cell survival activity.[7]

Splice variants are

arginyl aminopeptidase, MMP9, MMP10, cathepsin G, plasma kallikrein, plasmin, thrombin and trypsin.[25] C-terminal proteoforms, like intact lacritin, are selectively deficient in dry eye tears.[25]

Cell targeting

Lacritin targets a restricted group of epithelial cells (including human corneal epithelia), and not fibroblastic, glioma, or lymphoblastic cells.

syndecan-1 is partly responsible.[16][17]

Biotinylated cell surface proteins from a lacritin-responsive cell were incubated with lacritin under conditions of physiological salt. Those that bound lacritin were sequenced by

siRNA depletion.[16] Binding was restored by spiking in exogenous heparanase or heparitinase.[16] Thus, heparanase regulates lacritin function as an 'on-switch'. Exposed 3-O sulfated groups on heparanase-cleaved heparan sulfate[17] (that likely interacts with the cationic face of lacritin's C-terminal amphipathic alpha helix), and an N-terminal chondroitin sulfate chain (likely also binds to the cationic face) appear to contribute to binding.[17] Point mutagenesis of lacritin has narrowed the ligation site.[17] This novel heparanase mechanism appears at first glance to be poor for ocular health since heparanase release from invading lymphocytes in the corneal stroma is inflammatory. Yet heparanase is a normal secretory product of the corneal epithelium.[26]

Lacritin-dependent mitogenesis is inhibitable by pertussis toxin,.[18] The implication is that another key element of lacritin targeting specificity is a G-protein-coupled receptor that would presumably form a cell surface targeting complex with SDC1. Involvement of a G-protein coupled receptor would explain the rapidity of lacritin signaling.

Function

Lacritin is a

dry eye,[31] but also in blepharitis.[32]

Lacritin is an LFU prosecretory mitogen and survival factor with a biphasic dose response that is optimal at 1 - 10 nM for human

bell-shaped curve, with doses lower or higher than the dose optimum less effective. Other mitogens share this property.[18] However, in secretion assays using monkey lacritin on monkey lacrimal acinar cells, the dose response appears to be sigmoidal with increasing lipocalin or lactoferrin secretion through a narrow 0.1, 0.3 and 1 μM dose range.[6] Lacritin flows downstream from the lacrimal gland through ducts onto the eye
.

Artificial depletion of lacritin from normal human tears revealed that tears lacking lacritin are unable to promote the survival of ocular surface cells stressed with inflammatory cytokines.[7] Human dry eye tears also lack this activity. However, dry eye tears supplemented with lacritin are fully protective.[7] Similarly, tears artificially depleted of lacritin are deficient in bactericidal activity.[9] The antibody used to deplete lacritin also depletes C-terminal proteoforms.[25] These observations suggest that among all tear proteins, lacritin may be the master protector.

Dry eye tears are subject to premature collapse, as are normal human tears artificially depleted of C-terminal proteoforms.[25] In both cases, stability is largely restored by spiking in synthetic lacritin peptides N-94 or N-94/C-6 as proxy C-terminal proteoforms.[25] Each peptide inserts rapidly into (O-acyl)-omega-hydroxy fatty acid (OAHFA)[25] thought to reside at the aqueous lipid boundary in tears. OAHFA is the only class of tear lipids apparently downregulated in dry eye.[34]

Signaling

Lacritin mitogenic, survival and secretion signaling have been studied.

Lacritin mitogenic signaling[18] follows two pathways:

Rapid dephosphorylation of PKCα causes it to transiently move from the cytoplasm to the area of the Golgi apparatus and peripheral nucleus. Here, it forms a complex with PKCα and PLCγ2 from which downstream mTOR and NFAT signaling is initiated.

G-protein-coupled receptor
(GPCR). A candidate GPCR is under study. Syndecan-1 likely serves as a co-receptor. Binding lacritin may improve its GPCR affinity.

Lacritin survival signaling is observed when cells are stressed.[7] Lacritin promotes survival and homeostasis by transiently stimulating autophagy.[7] The mechanism appears to involve lacritin stimulated acetylation of the transcription factor FOXO3. Acetylated FOXO3 serves as a ligand for the autophagic mediator ATG101. Lacritin also promotes coupling of FOXO1 (that becomes acetylated with stress) with autophagic mediator ATG7. In the absence of lacritin, no coupling is observed.[7] Thus acetylation alone is likely insufficient for FOXO1-ATG7 ligation, unlike an initial claim.[35] Lacritin also restores oxidative phosphorylation and other metabolic events to rescue cells from stress.[7]

Lacritin stimulated secretion of tear proteins lipocalin and lactoferrin from monkey lacrimal acinar cells does not appear to be mediated by Ca2+, unlike the agonist carbachol.[6] When monkey lacrimal acinar cells are stressed with inflammatory cytokines (as occurs in dry eye), carbachol loses its capacity to promote the secretion of lipocalin. However, lacritin stimulates lipocalin secretion even in the presence of stress.[6]

Distribution

Species

Genomic sequencing assembled by

Ensembl reveals the existence of putative lacritin orthologues in other species.[36] Comparative genomic alignment suggests that horse lacritin is most similar to human lacritin among all non-primate sequences examined.[31] Moreover, it is detectable in horse tears by immunoblotting or by ELISA.[37] Antibodies directed to the C-, but not N-, terminus of human lacritin are most effective[37] - in keeping with the predicted conservation of the C-terminal amphipathic alpha helix[37] necessary for cell targeting.[16]

Tissue

Tissue distribution has been examined in humans and monkeys. Lacritin is most highly expressed in the

lacrimal functional unit (LFU). Viewed collectively, the LFU is the primary source of lacritin in the body, and the eye the main target.[4]

Disease

Unigene (the 'mammary gland' hit is for breast cancer) and gene array studies,[39] but some breast cancers appear to display elevated expression[39] or LACRT gene amplification.[47] iTRAQ analysis of tears from diabetics at different stages of disease detected relatively more lacritin, lysozyme, lipophilin A, lipocalin 1, immunoglobulin lambda chain and lactotransferrin in tears of patients with diabetic retinopathy. The analysis did not distinguish lacritin monomer from polymer, and proposed the application of all as biomarkers.[48] Tear lacritin monomer is barely detectable in the initial stage of infection by Fusarium solani in fungal keratitis.[49] Also down regulated are tear lipocalin-1 and cystatin S.[49] Fungal keratitis accounts for half of all corneal ulcers in Africa and India[50][51][52] - the primary source of blindness in these countries.[53] Phase II clinical trial of 'Lacripep™ in Subjects With Dry Eye Associated With Primary Sjögren's Syndrome' (NCT03226444)[54]
is complete. Lacripep™ is lacritin synthetic peptide 'N-94/C-6'.

References

  1. ^ a b c GRCh38: Ensembl release 89: ENSG00000135413Ensembl, May 2017
  2. ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  3. ^ "Entrez Gene: LACRT lacritin".
  4. ^
    PMID 11419941
    .
  5. ^ "Lacritin and Dry Eye". Facebook.
  6. ^
    PMID 23482462
    .
  7. ^ .
  8. ^ .
  9. ^ .
  10. ^ .
  11. ^ .
  12. ^ .
  13. ^ .
  14. ^ .
  15. ^ .
  16. ^ .
  17. ^ .
  18. ^ .
  19. ^ "ENSG00000135413". In Silico Transcriptomics Online. Molecular Kinetics. 2008-04-29.
  20. PMID 19187007
    .
  21. ^ .
  22. ^ "Homo sapiens gene LACRT, encoding lacritin". The AceView genes. National Center for Biotechnology Information (NCBI), U.S. National Library of Medicine.
  23. PMID 15851553
    .
  24. .
  25. ^ .
  26. .
  27. ^ "LACRT".
  28. ^ a b "PPD".
  29. ^ a b "LOC90070".
  30. PMID 36044852
    .
  31. ^ .
  32. ^ .
  33. .
  34. .
  35. .
  36. ^ "Gene report for ENSG00000135413". Ensembl release 72: Homo sapiens. EMBL-EBI and the Sanger Centre.
  37. ^
    PMID 22871838
    .
  38. ^ "Expression Profile Viewer: Hs.307096". UniGene. National Center for Biotechnology Information (NCBI), United States National Institutes of Health.
  39. ^ a b c "LACRT ENSG00000135413". Insilico Transcriptomics Online. GeneSapiens. 2008-04-29.[permanent dead link]
  40. ^ "HuPA_00022".
  41. PMID 20375347
    .
  42. .
  43. .
  44. .
  45. .
  46. .
  47. .
  48. .
  49. ^ .
  50. .
  51. .
  52. .
  53. .
  54. ^ "Lacripep™ in Subjects With Dry Eye Associated With Primary Sjögren's Syndrome2".

Further reading

External links